06160.HK
BeOne Medicines AG
HKSE · Healthcare · Biotechnology · CH
HKD 220.80
+1.19%Year over year
Reported trailing growth
- Revenue
- +34.2%
- EBITDA
- +1137.1%
- EBIT
- +1015.7%
- EPS
- +454.6%
- Free cash flow
- +696.5%
- Operating cash flow
- +160.6%
Forward estimates
Based on analyst estimates
- Revenue
- +18.0%
- EBITDA
- +25.3%
- EPS
- +32.7%
Three-year CAGR
- Revenue
- +55.8%
- EBITDA
- +248.7%
- EBIT
- +178.8%
- Net income
- +144.6%
- EPS
- +142.6%
- Free cash flow
- +240.8%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026